New Blood Test May Detect Cte in Living Former Football Players, Researchers Find

Chronic traumatic encephalopathy (CTE) has long presented a significant challenge for former athletes experiencing memory problems, mood changes and other neurological difficulties. Although the condition has been linked to repeated blows to the head, doctors have been unable to confirm its presence in living patients.
That could eventually change following new research suggesting that a blood test may help identify CTE in former football players.
A study led by researchers at Boston University and Banner Health, published in the Journal of the American Medical Association on 19 November, found significantly higher blood levels of a protein called eMTBR-tau in former football players whose autopsies later confirmed advanced CTE.
The findings offer hope that the condition could one day be detected during a person's lifetime, potentially allowing patients to receive more targeted care and helping researchers develop treatments.
Blood Test Identifies a Potential CTE Biomarker
The research team examined blood samples from 21 former American football players who had agreed to donate their brains for scientific research after death.
Autopsies confirmed that 18 participants had CTE, including 16 with advanced disease. The remaining three had no evidence of the condition.
Researchers measured levels of a protein fragment called endogenously cleaved microtubule-binding region tau, or eMTBR-tau. The protein is associated with tau tangles, abnormal accumulations that occur in the brains of people with certain neurodegenerative conditions.
The results showed significantly higher concentrations of eMTBR-tau in participants with high-stage CTE than in those with low-stage CTE or no CTE.
Five participants with CTE also showed Alzheimer's disease-related changes in their brain tissue, and their eMTBR-tau levels were the highest. However, another biomarker, phosphorylated tau 217 (p-tau217), which is associated with Alzheimer's disease, was elevated only in participants with Alzheimer's-related brain changes. This suggests that combining the two markers could eventually help distinguish between the conditions.
A separate study published in JAMA on 13 November also found elevated levels of eMTBR-tau243 in people with late-stage CTE, providing further evidence of a potential blood biomarker for the disease.
Why CTE Is Difficult to Diagnose
CTE is a progressive neurodegenerative disease associated with repeated head impacts, including those sustained through contact sports. It has also been identified in military personnel and others exposed to repeated head trauma.
The condition can affect thinking, memory, mood, behaviour and movement. Some people experience difficulties with impulse control, depression or aggression, although symptoms vary and can overlap with other neurological and mental health conditions.
According to researchers, CTE can currently only be definitively diagnosed through an examination of brain tissue after death. This makes it difficult for doctors to establish whether symptoms experienced by former athletes are caused by CTE or another condition.
If validated in larger studies, a blood test based on this biomarker could help researchers identify eligible participants for clinical trials and investigate treatments while patients are alive.
Researchers Warn the Findings Are Preliminary
Despite the excitement surrounding the discovery, the researchers cautioned against interpreting the results as proof that a clinically available CTE blood test is ready.
The study involved only 21 former male football players, just two of whom had early-stage CTE. Researchers also acknowledged the absence of age-matched controls. Larger studies involving more diverse participants are therefore needed to establish how reliably the biomarker identifies CTE, particularly in its earlier stages, and how it relates to clinical symptoms.
Michael Alosco, a co-senior author and co-director of clinical research at the Boston University CTE Centre, described the findings as an important step towards diagnosis during life.
He said further research would be needed to confirm the results and establish whether the test could eventually be used in clinical care.
The blood test has not yet been validated for clinical use and is not currently available as a diagnostic tool.
For former football players and others exposed to repeated head impacts, the research nevertheless represents a potentially significant development. If larger studies confirm the findings, doctors may eventually have a way to investigate CTE before death, bringing the prospect of earlier diagnosis and treatment closer.